Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Surgery Partners Inc (NASDAQ: SGRY) closed the day trading at $23.84 up 1.84% from the previous closing price of $23.41. In other words, the price has increased by $1.84 from its previous closing price. On the day, 0.88 million shares were traded. SGRY stock price reached its highest trading level at $24.1 during the session, while it also had its lowest trading level at $23.19.
Ratios:
For a better understanding of SGRY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.91 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.89. For the most recent quarter (mrq), Quick Ratio is recorded 1.66 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 14, 2024, initiated with a Buy rating and assigned the stock a target price of $38.
On June 28, 2024, Macquarie started tracking the stock assigning a Outperform rating and target price of $31.Macquarie initiated its Outperform rating on June 28, 2024, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’24 when Bradley Owens bought 9,241 shares for $30.69 per share.
Bane Harrison R. sold 6,325 shares of SGRY for $196,742 on Sep 04 ’24. The National Group President now owns 48,236 shares after completing the transaction at $31.11 per share. On Sep 04 ’24, another insider, Harrison Bane, who serves as the Officer of the company, bought 6,325 shares for $31.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 3030397696 and an Enterprise Value of 7947562496. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 2.662 whereas that against EBITDA is 13.337.
Stock Price History:
Over the past 52 weeks, SGRY has reached a high of $36.92, while it has fallen to a 52-week low of $21.36. The 50-Day Moving Average of the stock is -18.17%, while the 200-Day Moving Average is calculated to be -15.57%.
Shares Statistics:
Over the past 3-months, SGRY traded about 897.85K shares per day on average, while over the past 10 days, SGRY traded about 1513920 shares per day. A total of 126.59M shares are outstanding, with a floating share count of 73.98M. Insiders hold about 41.80% of the company’s shares, while institutions hold 68.02% stake in the company. Shares short for SGRY as of 1731628800 were 10070914 with a Short Ratio of 11.22, compared to 1728950400 on 10118737. Therefore, it implies a Short% of Shares Outstanding of 10070914 and a Short% of Float of 17.44.
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate the current performance of Surgery Partners Inc (SGRY) in the stock market.The consensus estimate for the next quarter is $0.08, with high estimates of $0.19 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.95 and $0.65 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.02, with 11.0 analysts recommending between $1.58 and $0.57.
Revenue Estimates
11 analysts predict $828.99M in revenue for the current quarter. It ranges from a high estimate of $839.2M to a low estimate of $824.8M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $735.4MFor the next quarter, 11 analysts are estimating revenue of $802.02M. There is a high estimate of $818.3M for the next quarter, whereas the lowest estimate is $784.23M.
A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.09B, while the lowest revenue estimate was $3.07B, resulting in an average revenue estimate of $3.08B. In the same quarter a year ago, actual revenue was $2.74BBased on 12 analysts’ estimates, the company’s revenue will be $3.38B in the next fiscal year. The high estimate is $3.44B and the low estimate is $3.34B.
